Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance
This study has been completed.
Study NCT00046033 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: September 18, 2002 Last Updated: August 6, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Infection
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Lopinavir/ritonavir
Ritonavir
Saquinavir
Tenofovir disoproxil fumarate
Amprenavir
Additional drug interventions recognized in this trial
Lopinavir
Tenofovir
Tenofovir disoproxil
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antibiotics, Antitubercular
Antitubercular Agents
Antiviral Agents
Enzyme Inhibitors
HIV Protease Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Protease Inhibitors
Reverse Transcriptase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)
Back to top of Main Content
